Match Document Document Title
9040057 Method of diagnosing and preventing pneumococcal diseases using pneumococcal neuraminidases  
A method of providing protection against pneumococcal infection in a subject is disclosed. The method includes steps of administering to the subject a composition that includes combination of...
9040054 Hypoallergenic molecules  
The present invention relates to a hypoallergenic molecule consisting of Bet v Ia or an allergen having at least 40% identity to Bet v Ia comprising mutations of at least four amino acid residues...
9034339 Nucleic acid and amino acid sequences, and vaccine for the control of ectoparasite infestations in fish  
The present invention is related with the isolation and cloning of a new gene, the production of the protein encoded by this gene by using recombinant systems, and the use of this antigen in a...
9034337 Treatment and delay of outset of synucleinopathic and amyloidogenic disease  
The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such...
9034338 Nucleic acid and amino acid sequences, and vaccine for the control of ectoparasite infestations in fish  
The present invention is related with the isolation and cloning of a new gene, the production of the protein encoded by this gene by using recombinant systems, and the use of this antigen in a...
9034341 Control of RAGE fusion protein glycosylation and RAGE fusion protein compositions  
The invention relates to methods for controlling the glycosylation of a RAGE fusion protein. The invention also relates to compositions comprising an amount of a RAGE fusion protein where at least...
9028816 Polypeptides and polypeptide constructs comprising single domain antibodies directed against von Willebrand factor  
The present invention relates to polypeptides and polypeptide constructs comprising at least one single domain antibody directed against vWF, vWF A1 domain, A1 domain of activated vWF, vWF A3...
9029502 Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction  
Provided herein are compounds that inhibit a binding interaction between an epidermal growth factor receptor (EGFR) and a heat shock protein 90 (HSP90), as well as compositions, e.g.,...
9028842 Compositions and methods for treatment, research and therapeutic applications for malaria  
The present invention provides anti-Plasmodium immunogenic compositions comprising EVP1 (PFD0495c) or an antigenic portion thereof, as well as methods of immunizing against malaria employing these...
9023363 A1 moiety of cholera toxin A subunit as an adjuvant for mucosal and systemic vaccines  
The present invention relates to cholera toxin CTA1 protein fragments, adjuvant compositions, and methods relating to adjuvants for vaccines. The invention also relates to using recombinant CTA1...
9023364 Vaccine antigen capable of inducing cross-reacting and neutralizing antibody against high-risk-type human papillomavirus  
Disclosed is a vaccine antigen capable of inducing a cross-reacting and neutralizing antibody directed against a high-risk-type human papillomavirus. Specifically disclosed are: a chimeric protein...
9023367 Compositions comprising chimeric OSPA molecules and methods of use thereof  
The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA...
9023362 Immunological compositions as cancer therapeutics  
The present invention concerns antibodies that react immunologically with an epitope comprising VDKSRWQQG (SEQ ID NO: 1), including those that bind to cancer cells, and methods relating thereto....
9023796 ***WITHDRAWN PATENT AS PER THE LATEST USPTO WITHDRAWN LIST***
Antidotes for factor XA inhibitors and methods of using the same
 
The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially...
9017982 Non-wild-type organophosphorus acid anhydrolases for enzymatic decontamination  
Provided are non-wild-type organophosphorus acid anhydrolases that are capable of degrading (ethyl {2-[bis(propan-2-yl)amino]ethyl}sulfanyl) (methyl)phosphinate and other V-agents. Particular...
9017690 Epitopes related to coeliac disease  
The invention herein disclosed is related to epitopes useful in methods of diagnosing, treating, and preventing coeliac disease. Therapeutic compositions which comprise at least one epitope are...
9018360 Modified biotin-binding protein  
The present invention provides a modified biotin-binding protein comprising an amino acid sequence represented by SEQ ID NO: 2 or its modified sequence and having a biotin-binding activity and...
9012603 Peptides that block the binding of IgG to FcRn  
The invention relates to peptides which bind to human FcRn and inhibit binding of the Fc portion of an IgG to an FcRn, thereby modulating serum IgG levels. The disclosed compositions and methods...
9011867 Use of specific peptides in the preparation of a medicament for the treatment of monoclonal gammopathy of undetermined significance (MGUS) or of smoldering multiple myeloma (SMM)  
The present invention relates to the use of a peptide comprising or essentially consisting of a sequence motif as shown in SEQ ID NO: 1 for the preparation of a medicament for the treatment of...
9011871 Broad spectrum vaccine against typhoidal and non-typhoidal Salmonella disease  
The present invention is drawn to multivalent Salmonella enterica serovar conjugate vaccines comprising conjugates of S. Typhimurium, S. Enteritidis, S. Choleraesuis, S. Typhi, S. Paratyphi A and...
9005627 Contiguous overlapping peptides for treatment of ragweed pollen allergy  
Contiguous overlapping peptides (COPs) for the treatment of allergic patients by Specific Immunotherapy (SIT) are provided from the sequence of the major allergen of ragweed pollen Amb a 1. Such...
9006404 Endometriosis cell targeting peptide and uses thereof  
Provided herein are compositions and methods for selectively targeting an endometriosis cell.
9005908 Mycobacterial infections  
The present invention relates to Mycobacterial infections and provides a method of diagnosing infections of Mycobacterium avium subsp. paratuberculosis (Map), the causative agent of Johne's...
RE45467 Streptococcus suis polypeptides and polynucleotides encoding same and their use in vaccinal and diagnostic applications  
The present invention relates to the field of Streptococcus. More specifically, the present invention relates to the identification of polypeptides and polynucleotide sequences encoding the same...
9005630 Fusion proteins for the treatment of allergic diseases  
The present invention relates to a fusion protein comprising a first peptide and a second peptide linked together with a linker, wherein the first peptide is an allergen and the second peptide is...
9005631 Membrane proximal region of HIV gp41 anchored to the lipid layer of a virus-like particle vaccine  
Disclosed herein are isolated immunogens including variant hepatitis B surface antigens (HBsAgs). In an example, a variant HBsAg includes a HBsAg with one or more transmembrane domains of the...
8999291 Compositions and methods for the removal of biofilms  
This invention provides isolated or recombinant polypeptides that are useful to vaccinate individuals suffering from chronic/recurrent biofilm disease or as a therapeutic for those with an...
8999349 HMGB1-derived peptides enhance immune response to antigens  
The invention provides an immunostimulatory peptide containing the amino acid sequence SAFFLFCSE and uses thereof. The invention also provides an immunostimulatory peptide containing the amino...
8999347 Vaccines for malaria  
The present invention relates to a novel lipoprotein particle, methods for preparing and purifying the same, its use in medicine, particularly in the prevention of malarial infections,...
8999348 Variants of group 6 allergens of the true grasses having reduced allergeneity due to mutagenesis of proline residues  
The present invention relates to the preparation and use of recombinant variants of group 6 allergens of the Poaceae (true grasses), which are characterized by reduced IgE reactivity compared with...
8999346 Immunogenic control of tumours and tumour cells  
The present invention relates to the use of immunogenic peptides comprising a T-cell epitope derived from a tumour-associated antigen and a redox motif such as C-(X)2-[CST] or [CST]-(X)2-C in the...
8999329 Agonist antibody to human thrombopoietin receptor  
This invention provides an agonist antibody to a human thrombopoietin receptor (human c-Mpl), and pharmaceutical compositions comprising the same for use in treatment of thrombocytopenia. The...
8993266 Proproteins activatable interferon alpha  
The present disclosure provides for proprotein and activatable proprotein compositions. A proprotein contains a functional protein (i.e. a full length protein or functional fragment thereof) which...
8992942 Proteins expressed by Mycobacterium tuberculosis and not by BCG and their use as diagnostic reagents and vaccines  
The present invention is directed to reagents useful for generating immune responses to Mycobacterium tuberculosis and for diagnosing infection and disease in a subject that has been exposed to M....
8993524 Compositions and methods for targeted immunomodulatory antibodies and fusion proteins  
The present invention is based on the seminal discovery that targeted immunomodulatory antibodies and fusion proteins can counter act or reverse immune tolerance of cancer cells. Cancer cells are...
8986702 Antibodies and processes for preparing the same  
Provided herein are various processes for the improved production of antibody producing organisms, antibody producing tissues, antibody producing cells and antibodies. In certain embodiments,...
8986703 Peptide sequences and compositions  
Provided is a polypeptide composition comprising one or more polypeptides, which polypeptides are immunogenic in a vertebrate such that they cause the vertebrate to produce immune system cells...
8986700 Immunogenic lipopeptides comprising T-helper and cytotoxic T-lymphocyte (CTL) epitopes  
The present invention provides synthetic immunogenic lipopeptide molecules comprising co-linear T-helper and CTL epitopes, and methods for their production and use in the generation of primary and...
8980287 Anaplastic lymphoma kinase (ALK) as oncoantigen for lymphoma vaccination  
Use of intracytoplasmatic domain of Anaplastic Lymphoma Kinase (ALK) protein and/or a nucleic acid molecule encoding for the intracytoplasmatic domain of Anaplastic Lymphoma Kinase (ALK) protein,...
8981052 JNK inhibitor molecules  
JNK inhibitor molecules are described. In addition, methods for raising antibodies against such JNK inhibitor molecules are disclosed. These antibodies and cells producing these antibodies are...
8980574 Method for ameliorating radiation exposure effects with alpha-1 antitrypsin  
Embodiments described herein relate to compositions, methods and uses for alpha-1 antitrypsin (AAT) or derivatives or analogs or peptides or mutants thereof for treating a subject exposed to...
8974794 C(epsilon)mX peptides for inducing immune responses to human mIgE on B lymphocytes  
The invention pertains to methods of using CεmX peptides (e.g., GLAGGSAQSQRAPDRVL; SEQ ID NO:2) that can bind effectively induce immune responses to membrane-bound IgE (mIgE) expressed on the...
8974800 Proteins expressed by mycobacterium tuberculosis and not by BCG and their use as diagnostic reagents and vaccines  
The present invention is directed to reagents useful for generating immune responses to Mycobacterium tuberculosis and for diagnosing infection and disease in a subject that has been exposed to M....
8968745 Method of treating cancer with an HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the same  
Disclosed are: a peptide comprising an amino acid sequence composed of contiguous nine amino acid residues derived from a WT1 protein, wherein an amino acid residue at position 2 in the amino acid...
8969524 FVIII peptides for immune tolerance induction and immunodiagnostics  
The present invention is related to peptides that can be used to reduce the immune response against FVIII or to induce tolerance to human FVIII in patients with, e.g., hemophilia A. Furthermore,...
8961986 Peptide composition  
There is provided a method for selecting a tolerogenic peptide by selecting a peptide which is capable of binding to an MHC class I or II molecule without further processing. There is also...
8961981 Targeting the neuromuscular junction for treatment  
Compositions and methods for targeting therapeutic agents to neuromuscular junctions are disclosed. Also disclosed are methods for treating diseases and conditions affecting the neuromuscular...
8961984 Surface-coated structures and methods  
The present invention relates to a method for covalently attaching a compound to a stainless steel, tin, iron, or titanium substrate, by contacting exposed surface(s) of the substrate with a...
8961992 Epsigam fusion protein  
Epsi-gam provides a novel fusion protein with the ability to cross-link either of the FcεRI or FcεRII cell surface receptors with an FcγRIIb cell surface receptor in order to block IgE-mediated...
8962678 Senescence inhibitor  
Provision of a drug, a quasi-drug, and a food or beverage, which are effective for senescence inhibition, mitochondrial function improvement, muscle dysfunction inhibition, muscular atrophy...